UniProtKB/Swiss-Prot Q01726 : Variant p.Arg163Gln
Melanocyte-stimulating hormone receptor
Gene: MC1R
Feedback ?
Variant information
Variant position:
163
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Arginine (R) to Glutamine (Q) at position 163 (R163Q, p.Arg163Gln).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from large size and basic (R) to medium size and polar (Q)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Polymorphism:
Genetic variants in MC1R define the skin/hair/eye pigmentation variation locus 2 (SHEP2) [MIM:266300 ]. Hair, eye and skin pigmentation are among the most visible examples of human phenotypic variation, with a broad normal range that is subject to substantial geographic stratification. In the case of skin, individuals tend to have lighter pigmentation with increasing distance from the equator, with type I skin being the most lightly pigmented and type IV the most dark pigmented. By contrast, the majority of variation in human eye and hair color is found among individuals of European ancestry, with most other human populations fixed for brown eyes and black hair. Partial loss-of-function mutations are associated with fair skin, poor tanning and increased skin cancer risk.MC1R variants associated with red hair and fair skin, determine female-specific increased analgesia from kappa-opioid receptor agonist [MIM:613098]. -
Additional information on the polymorphism described.
Variant description:
Probable risk factor for developing melanoma; shows a moderate and not significant decrease of cAMP production to NDP-MSH stimulation; shows a not significant decrease in cAMP production at any concentrations of NDP-MSH stimulation.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
163
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
317
The length of the canonical sequence.
Location on the sequence:
YISIFYALRYHSIVTLPRAR
R AVAAIWVASVVFSTLFIAYY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human YISIFYALRYHSIVTLPRARR AVAAIWVASVVFSTLFIAYY
Gorilla YISIFYALRYRSIVTLPRARR AVAAIWVASVLFSTLFIAYY
YLSIFYALRYHSIVTLPRAWR AISAIWVASVLSSTLFIAYY
Rhesus macaque YISIFYALRYHSIVTLPRAQR AIAAIWVASVLCSTLFIAYY
Chimpanzee YISIFYALRYHSIVTLPRARR AIAAIWVASVLFSTLFIAYC
Mouse YISIFYALRYHSIVTLPRARR AVVGIWMVSIVSSTLFITYY
Pig YVSIFYALRYHSIVTLPRAGR AIAAIWAGSVLSSTLFIAYY
Bovine YISIFYALRYHSVVTLPRAWR IIAAIWVASILTSLLFITYY
Goat YISIFYALRYHSVVTLPRAWR IIAAIWVASILTSVLSITYY
Sheep YISIFYALRYHSVVTLPRAWR IIAAIWVASILTSVLSITYY
Cat YISIFYALRYHSIVTLPRAWR AISAIWVASVLSSTLFIAYY
Horse YISIFYALRYHSIMMLPRVWR AIVAIWVVSVLSSTLFIAYY
Chicken YITIFYALRYHSIMTLQRAVV TMASVWLASTVSSTVLITYY
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 317
Melanocyte-stimulating hormone receptor
Topological domain
141 – 163
Cytoplasmic
Helix
158 – 181
Literature citations
High polymorphism at the human melanocortin 1 receptor locus.
Rana B.K.; Hewett-Emmett D.; Jin L.; Chang B.H.; Sambuughin N.; Lin M.; Watkins S.; Bamshad M.; Jorde L.B.; Ramsay M.; Jenkins T.; Li W.H.;
Genetics 151:1547-1557(1999)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS GLN-67; GLU-84; MET-92; CYS-151 AND GLN-163;
Identification of novel functional variants of the melanocortin 1 receptor gene originated from Asians.
Nakayama K.; Soemantri A.; Jin F.; Dashnyam B.; Ohtsuka R.; Duanchang P.; Isa M.N.; Settheetham-Ishida W.; Harihara S.; Ishida T.;
Hum. Genet. 119:322-330(2006)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; FUNCTION; VARIANTS GLN-67; MET-92; THR-120; PHE-147 DEL; CYS-151; ILE-157; THR-159; GLN-163 AND GLY-166; CHARACTERIZATION OF VARIANTS GLN-67; MET-92; THR-120; PHE-147 DEL; CYS-151; ILE-157; THR-159; GLN-163 AND GLY-166;
Submission
SeattleSNPs variation discovery resource;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS LEU-60; MET-92; CYS-151; THR-155; LEU-156; TRP-160; GLN-163 AND LEU-196;
MC1R: three novel variants identified in a malignant melanoma association study in the Spanish population.
Fernandez L.; Milne R.; Bravo J.; Lopez J.; Aviles J.; Longo M.; Benitez J.; Lazaro P.; Ribas G.;
Carcinogenesis 28:1659-1664(2007)
Cited for: VARIANTS CMM5 PHE-41 AND THR-128; VARIANTS LEU-60; MET-92; THR-155; TRP-160; GLN-163; SER-281 AND HIS-294;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.